Member Info for sadoldgit

I could not resist a top up either, just 250k at 0 .692p

Which would be announced first ie the partnership or the grant? On the other side of the coin we could ask why would you give Sareum a grant if they require a partnership to complete the research and trials? I get a feeling there is a lot going on in the background.
As for time scales difficult to hazard a guess but with regards Tims video they do have 100's of grammes which can be made ready to use. if allowed fast track, surely could then start trial very soon ie days a couple of weeks at most.
All requires negotiating in the first place.
Perhaps Tim is in discussions,

If you look at the following link https://www.selleckchem.com/products/baricitinib-ly3009104.html you will see there is not one single Tyk 2 Jak 1 compound. The other are mainly JAK 1 and 2 or 1,2 and 3. As taken from Tims video.

Taking Baricitinib Jak 1 and Jak 2 (1st generation inhibitor) Jak 2 and Jak 3 are reportedly responsible for NDA black box warning for serious infections, lymphoma and thrombosis. According to Tim's presentation Jak2 and Jak 3 do not look promising in the field of treatment for Covid-19 as selective in wrong field.

Sareum 2nd generation inhibitor Tyk2 Jak 1 is the only available compound of its type and has the benefit of being administered orally.

I do not see a new patent in the US being granted for a compound which has a patent already in place ( the compound itself is protected) Being used as a combination therapy does not change anything. It is not for what use the patent is applied but to the actual chemical composition ie the compound that is protected. However, on the bright side it is protected I believe for a 20 year period from 2013.

I think you are spot on with that one Thoth!

That is interesting. Could you tell us what these treatments are called, who makes them and also their toxicity?

Celtic. Nobody has made an offer? By that I take it you mean that nobody has made a formal offer. If negotiations are in place then offers and compromises will be made at these non formal stages (you will never get to hear about them. With contracts it is common to have legal departments involved. Three important points with regards to Tyk2, firstly the results of research and that will include conclusive results from the DoD, secondly, the granting of a new patent and thirdly maximum tolerated dose levels.
As for the Biotrinity presentation.
If you have a car on your drive advertised for sale and you want 10 k for it and I come along as a buyer do I pay you the 10k or 5k that I am offering? If you not content with what I offer you will still advertise that for sale. I have now raised the price to 6k. Somebody else comes along and offers 7k. You do not divulge the details of one to the other. You have an interested other person. With two separate bidders buyers involved you will get very close to your asking price unless it is a bag of Sh11t. Not for one minute do I believe Tyk2 is not spot on. In the pharma industry there are massive multi billion dollar companies and they did not get where they are by being nice. Sareum is a minnow by comparison.
There will ultimately be delays in finalising an agreement due to the implications of Covid-19. It all takes time and the buyer needs to know exactly what he is buying (including patent expiry)and that means all research results which at the moment we do not have.
It is frustrating at times. For us we do not know and can only hypothesise on what little bit of info we can dig up. Yet, it will also be frustrating for the buyer and Sareum also. All down to key (call them milestone points or confirmations at pre contract) information being provided.
Regards and have a great day all.

I certainly would not rule a placing out. However, what price would Sareum put on the placing? The share price is a little volatile at the moment. If a placing did take place, it would mean they would be taking it into clinical trials and that would be a massive boost as then in clinical trials and not pre clinical. That is a milestone in itself and feel sure it would not be such a bad thing.

I would be very interested as for what research purposes the DoD used Tyk2 for. DoD don't as a rule give away secrets. In addition there is also the problem with the granting of a new patent for SD 1801.
In my honest opinion talks are going on with regards to Tyk 2 but the buyer, whoever that may be, wants it on the cheap and or certain conditions with respect to pre clinical results and patents. There maybe more than one interested party. Unfortunately these discussions/negotiations take time. Are there attempts to strangle Sareum financially, pushing them into selling or licensing on the buyers prices and or terms.

However, with regards to purchasing or licensing a deal as a buyer would you not want to know first the conclusion of the results of the research into Tyk2 by the DoD? As for the granting of a new patent that would have massive impact on the price of purchase or licensing. Could Tyk2 be used as a successful treatment for Covid-19?. There are so many loose ends at the moment .
At the moment it does appear to me to be a bit of a waiting game for Sareum.

Sareum are still waiting for milestone payments for CHK1. Sierra really are dragging their heels ( a milestone payment would be enough to finance early stages of clinical trials on Tyk2).
I am sure we will hear something in the not too distant future.

Overall , I don't think a placing would be a bad thing, certainly not in the long term.
Back to my beer.
Regards

A good idea, I did the same. Price drop in my opinion due to day traders realising profit for the week. Can always take the opportunity to add a few at these prices.
Regards.

That is a very interesting thought Andy. Time will tell.

Attachment of latest review of Remsidivir in The Lancet:- https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31022-9.pdf

Interesting light read on viruses :-https://sciencing.com/did-cold-viruses-come-from-6647005.html

I don't care either if it was a buy or sell. Wilfred enquired and I responded!

More importantly I believe the testing would be used prior to entering your work place. Millions should be at work but as they do not know if they have the virus and the health authorities do not know either then government policy is stay at home to prevent the spread. early diagnosis leads to early treat which in most cases leads to recovery. People need to be treated and monitored at the first signs not when they are admitted to hospital at deaths door.
Regards
Ps I did add today at a pound each.

3 million trade. If you look at the time of trade @16.36hrs 28/04/20/ trading price was 0.78 to 0.80p. The time this delayed trade comes up it is not the previous days half past 4 price which would indicate a buy price but, it is time the delayed trade is entered and at this time twas 0.80 to 0.83p so in this instance being below the midrange price looks like a sell.
In my own opinion (for what little it is worth) the trade should be shown as a buy or a sell irrespective of midrange prices.

Good spot krone. Looking very promising for Tyk2! Negotiations still going on I would hesitate to guess. Time consuming as it will take time to get contracts made up and a formal offer made. Unfortunately we don't get to know at what stage negotiations are at.

Attending Bio Trinity should turn up the heat on any potential licensing partners that Sareum are in talks with. Looking good and just a matter of time.
Regards

I have the same feeling!

Welcome aboard JSablefur! The potential is there and until we get a positive update I cannot see it myself moving much either up or down. It will pay to look through the Sareum website on past news releases.
As I am sure you are aware we have Tyk 2 ( 2 compounds), FLT+3 which has been recently licensed to the Chinese and CHK1 ( very promising results and potential for a wider application with other treatments). We are all awaiting (some longer than others) for further updates on these compounds.
Regards.

Carli £0.002 a month ago. Did you buy in at these prices or not? You claim to hold shares and rubbish Sar along with some of the decent posters on here.
You are saying that SAR has nothing then why invest in the first place. If and when a little red dot appears with good, proper, factual updates and news, then the present price will rise markedly. Do you agree with that statement? If you do not, then what may I ask is your objective here as a claimed share holder?

Last concluding paragraph from their report follows if anyone is interested (April 2017):-

An additional benefit of human lung tissue in comparison to mouse models is that the human lung tissue can be directly infected with viral and bacterial strains isolated from infected patients, which therefore strengthens the relevance of the data. The disclosure of immune differences between mice and humans, as shown in this study, is of particular importance, since factors such as GM-CSF are already used in clinical trials and considered for immune modulatory treatment in acute lung injury. Moreover, we suggest pharmacological Tyk2 inhibition as an immune modulatory intervention strategy to sustain the crucial endogenous GM-CSF levels in severe viral/bacterial pneumonia.